as 03-31-2025 9:54am EST
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.
Founded: | 2016 | Country: | United States |
Employees: | N/A | City: | SOUTH SAN FRANCISCO |
Market Cap: | 113.6M | IPO Year: | 2021 |
Target Price: | $8.60 | AVG Volume (30 days): | 6.1M |
Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.31 | EPS Growth: | N/A |
52 Week Low/High: | $0.39 - $5.25 | Next Earning Date: | 03-10-2025 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Tingley Whittemore | TNYA | Chief Medical Officer | Mar 10 '25 | Sell | $0.54 | 7,398 | $3,983.08 | 180,464 | |
Ali Faraz | TNYA | Chief Executive Officer | Mar 10 '25 | Sell | $0.54 | 9,741 | $5,244.55 | 324,461 | |
Higa Tomohiro | TNYA | SVP, Finance | Mar 10 '25 | Sell | $0.54 | 2,482 | $1,336.31 | 101,155 | |
COLUMN GROUP III GP, LP | TNYA | 10% Owner | Mar 5 '25 | Buy | $0.70 | 35,714,284 | $24,999,998.80 | 49,313,559 | |
GOEDDEL DAVID V | TNYA | Director10% Owner | Mar 5 '25 | Buy | $0.70 | 35,714,284 | $24,999,998.80 | 49,313,559 |
TNYA Breaking Stock News: Dive into TNYA Ticker-Specific Updates for Smart Investing
GlobeNewswire
21 minutes ago
Insider Monkey
3 days ago
Insider Monkey
6 days ago
TipRanks
6 days ago
MT Newswires
7 days ago
Simply Wall St.
7 days ago
GlobeNewswire
7 days ago
GlobeNewswire
12 days ago
The information presented on this page, "TNYA Tenaya Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.